Leptospirosis,
also known as Weil's disease, is a bacterial infection caused by Leptospira
organisms, which are spread through contact with animal urine. It is one of the
most common zoonoses in the world. The rising prevalence of leptospirosis
worldwide and increasing government initiatives to control the disease are
propelling the growth of the global leptospirosis market. Leptospirosis
diagnostics play a vital role in early detection and treatment to prevent
severe complications.
The
global Leptospirosis Market is estimated to be valued at US$ 496.8 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Market key trends:
The
increasing demand for point-of-care (POC) testing is anticipated to drive the
market growth over the forecast period. POC tests enable rapid diagnosis which
is crucial for effective treatment, especially when patients present with
flu-like symptoms. Rapid diagnostic tests provide results within 30 minutes as
compared to conventional tests which require specialized laboratory
infrastructure and take 1-2 weeks for results. Major players are focusing on
developing and commercializing innovative POC test kits such as TRUDIAG
Leptospirosis rapid test cassette from Groupe Pharmaceutical. Widespread
adoption of such advanced diagnostics for prompt detection is expected to boost
the leptospirosis market.
Segment Analysis
The global leptospirosis market is dominated by the diagnostics segment. This
segment accounts for the largest market share owing to the rising prevalence of
leptospirosis globally which has increased the demand for accurate diagnostic
tests. Within diagnostics, serological tests sub-segment dominates due to
greater utilization of immunoassays and molecular assays for diagnosis. These
tests provide reliable diagnosis in the early stages of infection.
Key Takeaways
The
Global
Leptospirosis Market Size is
expected to witness high growth over the forecast period of 2023-2030. The
rising incidence of leptospirosis infections globally due to changing
environmental conditions and growing animal-human transmission is driving
market growth.
Regional analysis
North America is projected to be the fastest growing regional market during the
forecast period. This is attributed to the presence of sophisticated healthcare
facilities, increasing prevalence of zoonotic infections, and supportive
government policies in the region. The Asia Pacific dominates the global market
and is expected to continue its dominance over the forecast years. The
dominance is driven by the large patient pool, increasing healthcare
investments, and growing awareness about zoonotic infections.
Key players
Key players operating in the leptospirosis market are USAntibiotics, Dr.
Reddy€TMs Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group
Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La
Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT,
Haustus Biotech Pvt. Ltd., and Aden Healthcare. These players are focusing on
developing and commercializing innovative diagnostic tests and vaccines to
strengthen their market position. Collaboration activities with research
institutes are also among the adopted strategies.
Get
more insights on this topic:
https://www.marketwebjournal.com/leptospirosis-market-size-market-share-analysis/
Comments
Post a Comment